This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Becker, T. M. Articles by Mann, G. J. Search for Related Content PubMed PubMed Citation Articles by Becker, T. M. Articles by Mann, G. J.

Functional Impairment of Melanoma-associated p16^INK4a Mutants in Melanoma Cells despite Retention of Cyclin-dependent Kinase 4 Binding¹

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, NSW 2145, Australia

Purpose: Melanoma-associated germ-line mutations affecting the tumor suppressor and cyclin-dependent kinase (CDK) inhibitor, CDKN2A/p16^INK4a have been identified in >100 melanoma-prone families. To predict the melanoma risk for carriers of specific mutations, it is useful to test the function of the mutant proteins in biochemical assays; however, it is unclear how well these results correlate with their cellular effects. We examined the relationship between loss of CDK binding by mutant proteins and various measures of cellular growth in melanoma cells.

Experimental Design: The cellular activities of four melanoma-associated p16^INK4a mutations (Arg24Pro, Ala36Pro, Met53Ile, and Val126Asp) were compared by use of inducible expression in stably transfected melanoma cells, deficient in expression of the endogenous protein, and compared with their ability to bind CDK4.

Results: The cell cycle-inhibitory activity of all of the mutants was profoundly reduced, and partially retained capacity for CDK4 binding in functional assays did not correlate with significant preservation of cell cycle-regulatory function.

Conclusion: Testing of p16^INK4a interactions with CDKs in protein-binding assays is an unreliable predictor of mutant p16^INK4a function in cells. In addition to exhibiting reduced stability, these mutant proteins may also be defective in interaction with cellular targets other than CDKs.

This article has been cited by other articles:

				R. Jones, M. Ruas, F. Gregory, S. Moulin, D. Delia, S. Manoukian, J. Rowe, S. Brookes, and G. Peters A CDKN2A Mutation in Familial Melanoma that Abrogates Binding of p16INK4a to CDK4 but not CDK6 Cancer Res., October 1, 2007; 67(19): 9134 - 9141. [Abstract] [Full Text] [PDF]

				H. Rizos, H. A. McKenzie, A. L. Ayub, S. Woodruff, T. M. Becker, L. L. Scurr, J. Stahl, and R. F. Kefford Physical and Functional Interaction of the p14ARF Tumor Suppressor with Ribosomes J. Biol. Chem., December 8, 2006; 281(49): 38080 - 38088. [Abstract] [Full Text] [PDF]

				M T Landi, A M Goldstein, S Tsang, D Munroe, W Modi, M Ter-Minassian, R Steighner, M Dean, N Metheny, B Staats, et al. Genetic susceptibility in familial melanoma from northeastern Italy J. Med. Genet., July 1, 2004; 41(7): 557 - 566. [Full Text] [PDF]

				L. K. Mosavi, T. J. Cammett, D. C. Desrosiers, and Z.-y. Peng The ankyrin repeat as molecular architecture for protein recognition Protein Sci., June 1, 2004; 13(6): 1435 - 1448. [Abstract] [Full Text] [PDF]